Shots:
- J&J has entered strategic agreements & collaboration with Sail to advance its lead immune-mediated disease program & in vivo CAR-T platform, with the potential to expand the platform across additional therapeutic targets
- As per the deal, Sail will receive initial payments of $785M, incl. a $465M equity investment, with additional contingent payments of ~$140M tied to development milestones
- Additionally, J&J was granted an exclusive option to acquire Sail for $2.58B, which if exercised, is expected to dilute adjusted EPS by ~$0.18 in 2026 & ~$1.28 in 2027
Ref: Businesswire | Image: J&J and Sail | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
